In the open-label period of the study, application site reactions were reported in three (3/219; 1.4%) additional patients that were treated with AndroGel 1.62%. These adverse reactions included 6 reports of PSA increased, 2 of hematocrit increased, and 1 each of triglycerides increased and prostate cancer. Used AndroGel 1.62% pumps or used AndroGel 1.62% packets should be discarded in household trash in a manner that prevents accidental application or ingestion by children or pets. Each packet of 1.25 g or 2.5 g gel contains 20.25 mg or 40.5 mg testosterone, respectively. When using packets, the entire contents should be squeezed into the palm of the hand and immediately applied to the application sites.
Tell your healthcare provider about all of the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements. AndroGel (testosterone gel) 1% CIII is available packaged with 2 x 75 g pumps (each pump dispenses 60 metered 1.25 g doses) or in a box of 30 packets with 2.5g or 5g gel. A single 24 (+1) hour application of duplicate patches containing test articles (placebo gel, testosterone gel, or saline) was made to naive skin sites on Day 1. In patients treated with AndroGel, there were no observed differences in the average daily serum testosterone concentrations at steady-state based on age, cause of hypogonadism, or body mass index. In a study with 10 g of AndroGel, all patients showed an increase in serum testosterone within 30 minutes, and eight of nine patients had a serum testosterone concentration within normal range by 4 hours after the initial application. Approximately 10% of the testosterone dose applied on the skin surface from AndroGel is absorbed into systemic circulation.
There is considerable variation in the half-life of testosterone as reported in the literature, ranging from 10 to 100 minutes. Approximately 40% of testosterone in plasma is bound to SHBG, 2% remains unbound (free) and the rest is bound to albumin and other proteins. Serum concentrations approximate the steady-state level by the end of the first 24 hours and are at steady state by the second or third day of dosing.
ANDROGEL 1.62% can transfer from your body to others including, children and women. The mean estradiol and DHT concentration profiles paralleled the changes observed in testosterone. Dose titrations on Days 14, 28, and 42 resulted in final doses of 20.25 mg â€" 81 mg on Day 112 as shown in Table 6. The percentages of patients with Cmax greater than 1500 ng/dL, and between 1800 and 2499 ng/dL on Day 112 were 11.2% and 5.5%, respectively. The secondary endpoint was the percentage of patients, with Cmax above three pre-determined limits. In patients treated with AndroGel 1.62%, 81.6% (146/179) had Cavg within the normal range at Day 112. The gauze pads were then analyzed for residual testosterone content.
If you become pregnant, contact your health care provider right away. Do not use topical testosterone if you are pregnant or may become pregnant. Your pharmacist can tell you all of the ingredients in the specific topical testosterone products they stock. People who are allergic to any of the following should not use topical testosterone. Call your health care provider if your blood pressure increases while using this medicine. Keep all appointments with your health care provider to check your blood.
Patients could agree to continue in an open-label, active treatment maintenance period of the study for an additional 182 days. Patients were randomized to receive active treatment or placebo using a rotation method utilizing the abdomen and upper arms/shoulders for 182 days. The decreases in levels of LH and FSH are consistent with reports published in the literature of long-term treatment with testosterone. The levels of LH and FSH decreased with testosterone treatment. In that group, 78% (106/136) had average serum testosterone concentrations in the normal range at Day 364.
Cases of secondary exposure resulting in virilization of children have been reported in postmarketing surveillance of testosterone gel products. In diabetic patients, the metabolic effects of androgens may decrease blood glucose and, therefore, may decrease insulin requirements. In at least one reported case, the reporter considered the possibility of secondary exposure from items such as the testosterone gel user's shirts and/or other fabric, such as towels and sheets see WARNINGS AND PRECAUTIONS. In most cases with a reported outcome, these signs and symptoms were reported to have regressed with removal of the testosterone gel exposure. Cases of secondary exposure to testosterone resulting in virilization of children have been reported in postmarketing surveillance of testosterone gel products.
MedicineNet does not provide medical advice, diagnosis or treatment. The FDA approved Androgel in February 2000. Other testosterone replacement products include Androderm, Axiron, Testim, and Fortesta. Since your doctor may adjust your dose based on your body’s response to therapy, make it a priority to schedule and attend your follow-up appointments. The recommended starting dose of AndroGel 1.62% is 40.5 mg.
The mean steady-state DHT/T ratio during 180 days of AndroGel treatment remained within normal limits and ranged from 0.23 to 0.29 (5 g/day) and from 0.27 to 0.33 (10 g/day). The average (± SD) daily testosterone concentration produced by AndroGel 10 g on Day 30 was 792 (± 294) ng/dL and by AndroGel 5 g 566 (± 262) ng/dL. Figure 1 summarizes the 24-hour pharmacokinetic profiles of testosterone for hypogonadal men (less than 300 ng/dL) maintained on 5 g or 10 g of AndroGel for 30 days. The skin serves as a reservoir for the sustained release of testosterone into the systemic circulation.

Gender: Female

Social links